DRIO
DarioHealth Corp.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$7.14
+2.29%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 21.0M | 22.4M | 27.0M | 20.4M | 27.7M |
| Cost of Revenue | 9.2M | 9.7M | 13.8M | 14.4M | 18.0M |
| Gross Profit | 11.8M | 12.7M | 13.3M | 6.0M | 9.7M |
| Operating Expenses | |||||
| R&D Expense | 10.4M | 13.8M | 24.2M | 20.2M | 19.6M |
| SG&A Expense | 33.6M | 35.5M | 46.8M | 41.8M | 46.8M |
| General & Admin Expense | 14.5M | 15.2M | 20.5M | 18.0M | 16.5M |
| Selling & Marketing Expense | 19.1M | 20.3M | 26.4M | 23.8M | 30.3M |
| Other Expenses | 36.8M | — | — | 128.0K | — |
| Total Operating Expenses | 80.8M | 49.3M | 71.0M | 62.2M | 66.5M |
| Cost and Expenses | 90.1M | 59.0M | 84.8M | 76.4M | 84.5M |
| Operating Income (EBIT) | (69.1M) | (36.7M) | (57.7M) | (56.2M) | (56.8M) |
| Non-Operating | |||||
| Interest Income | 577.0K | 943.0K | 1.1M | 1.9M | 506.0K |
| Interest Expense | 5.6M | 3.4M | 96.0K | 645.0K | 2.7M |
| Net Interest Income | (5.0M) | (2.4M) | 1.0M | 1.2M | (2.2M) |
| Other Non-Op Income/Expense | 137.2M | (5.0M) | 13.1M | (3.2M) | (5.4M) |
| Non-Operating Income (excl Interest) | (37.5M) | 1.6M | (13.2M) | 3.2M | 3.5M |
| EBT (Pre-Tax Income) | 68.1M | (41.6M) | (44.6M) | (59.4M) | (62.2M) |
| Income Tax Expense | 363.0K | 105.0K | (1.9M) | 64.0K | 4.0K |
| Bottom Line | |||||
| Net Income | 67.8M | (41.7M) | (42.7M) | (59.4M) | (62.2M) |
| Earnings from Cont. Ops | 67.8M | (41.7M) | (42.7M) | (59.4M) | (62.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 68.4M | (40.3M) | (30.1M) | (54.9M) | (63.8M) |
| Per Share | |||||
| Basic EPS | $0.69 | ($0.81) | ($0.74) | ($1.93) | ($2.63) |
| Diluted EPS | $0.69 | ($0.81) | ($0.74) | ($1.93) | ($2.63) |
| Revenue Per Share | $2.25 | $0.45 | $0.67 | $0.72 | $1.17 |
| Shares | |||||
| Basic Shares Outstanding | 9.3M | 49.6M | 40.4M | 28.4M | 23.6M |
| Diluted Shares Outstanding | 9.3M | 49.6M | 40.4M | 28.4M | 23.6M |
| Profitability Metrics | |||||
| EBITDA | (29.7M) | (34.7M) | (37.1M) | (54.4M) | (55.6M) |
| D&A | 1.8M | 3.6M | 7.4M | 5.0M | 4.7M |
| EBIT | (31.6M) | (38.3M) | (44.5M) | (59.4M) | (60.3M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026